Cambridge Investment Research Advisors Inc. Has $81.31 Million Holdings in Eli Lilly and Company (NYSE:LLY)

Cambridge Investment Research Advisors Inc. grew its stake in Eli Lilly and Company (NYSE:LLY) by 13.4% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 173,375 shares of the company’s stock after buying an additional 20,551 shares during the quarter. Cambridge Investment Research Advisors Inc.’s holdings in Eli Lilly and Company were worth $81,310,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in LLY. Oxler Private Wealth LLC raised its position in Eli Lilly and Company by 0.4% during the first quarter. Oxler Private Wealth LLC now owns 6,050 shares of the company’s stock worth $2,078,000 after acquiring an additional 24 shares in the last quarter. Missouri Trust & Investment Co grew its stake in shares of Eli Lilly and Company by 3.2% in the first quarter. Missouri Trust & Investment Co now owns 774 shares of the company’s stock valued at $266,000 after acquiring an additional 24 shares in the last quarter. Silvercrest Asset Management Group LLC grew its stake in Eli Lilly and Company by 0.6% during the first quarter. Silvercrest Asset Management Group LLC now owns 4,331 shares of the company’s stock worth $1,487,000 after buying an additional 25 shares in the last quarter. Cora Capital Advisors LLC grew its stake in Eli Lilly and Company by 2.8% during the first quarter. Cora Capital Advisors LLC now owns 956 shares of the company’s stock worth $328,000 after buying an additional 26 shares in the last quarter. Finally, Sittner & Nelson LLC grew its stake in Eli Lilly and Company by 2.7% during the first quarter. Sittner & Nelson LLC now owns 1,003 shares of the company’s stock worth $344,000 after buying an additional 26 shares in the last quarter. Institutional investors own 81.38% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 591 shares of the firm’s stock in a transaction that occurred on Friday, July 21st. The stock was sold at an average price of $466.62, for a total value of $275,772.42. Following the transaction, the insider now owns 101,028,219 shares in the company, valued at $47,141,787,549.78. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, major shareholder Lilly Endowment Inc sold 591 shares of the firm’s stock in a transaction that occurred on Friday, July 21st. The stock was sold at an average price of $466.62, for a total value of $275,772.42. Following the transaction, the insider now owns 101,028,219 shares in the company, valued at $47,141,787,549.78. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Donald A. Zakrowski sold 600 shares of the firm’s stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $546.51, for a total value of $327,906.00. Following the completion of the transaction, the chief accounting officer now owns 5,378 shares in the company, valued at approximately $2,939,130.78. The disclosure for this sale can be found here. Over the last three months, insiders have sold 976,153 shares of company stock valued at $21,080,192,113. Company insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Morgan Stanley raised their price objective on shares of Eli Lilly and Company from $617.00 to $640.00 and gave the company an “overweight” rating in a report on Tuesday, September 5th. Berenberg Bank raised their price target on shares of Eli Lilly and Company from $375.00 to $500.00 in a report on Tuesday, June 20th. Wells Fargo & Company raised their price objective on shares of Eli Lilly and Company from $500.00 to $615.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 8th. Argus lifted their price target on shares of Eli Lilly and Company from $470.00 to $620.00 and gave the company a “buy” rating in a research report on Tuesday, September 5th. Finally, StockNews.com started coverage on shares of Eli Lilly and Company in a report on Thursday, August 17th. They set a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and twenty have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $532.78.

Eli Lilly and Company Stock Up 0.3 %

Shares of LLY traded up $1.46 during trading hours on Tuesday, hitting $572.74. The company had a trading volume of 1,195,288 shares, compared to its average volume of 3,026,915. The company has a market capitalization of $543.70 billion, a PE ratio of 80.02, a price-to-earnings-growth ratio of 2.37 and a beta of 0.32. The company has a current ratio of 1.13, a quick ratio of 0.87 and a debt-to-equity ratio of 1.63. Eli Lilly and Company has a one year low of $296.32 and a one year high of $601.84. The company’s fifty day moving average price is $512.56 and its two-hundred day moving average price is $439.28.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, August 8th. The company reported $2.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.98 by $0.13. The company had revenue of $8.31 billion for the quarter, compared to analyst estimates of $7.58 billion. Eli Lilly and Company had a return on equity of 65.00% and a net margin of 22.01%. The firm’s quarterly revenue was up 28.1% compared to the same quarter last year. During the same period in the prior year, the company posted $1.25 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 9.84 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th were issued a $1.13 dividend. This represents a $4.52 annualized dividend and a yield of 0.79%. The ex-dividend date of this dividend was Monday, August 14th. Eli Lilly and Company’s payout ratio is currently 62.87%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.